<DOC>
	<DOCNO>NCT01175733</DOCNO>
	<brief_summary>The purpose study investigate whether addition panitumumab radiotherapy plus gemcitabine increase number patient alive progression free 7 month .</brief_summary>
	<brief_title>Chemoradiation With Gemcitabine Combination With Panitumumab Patients With Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This phase I/II , multi-center dose escalation study . Phase I : Patients enrol cohort 3 per dose level MTD panitumumab establish . Phase II : Up approximately 56 patient treated MTD level panitumumab establish phase I part study . Based historic data patient pancreatic cancer treat gemcitabine base chemoradiation , aim increase number patient alive progression free 7 month historical value 50 % 70 % combination treatment chemoradiation plus panitumumab .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological cytological confirm pancreatic cancer . Not eligible curative resection . No distant metastasis present . Previously untreated chemotherapy anticancer biologicals current malignancy . No current malignant disease , except basal cell carcinoma skin . Measurable evaluable disease define RECIST 1.1 criterion . Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) Scale . Age ≥ 18 year . Adequate haematological biological function : Bone marrow function : 1 . Neutrophils ≥ 1.5 x 109/L 2 . Platelets ≥ 100 x 109/L 3 . Hb ≥ 6 mmol/L Hepatic function : 1 . AST/ALT alkaline phosphatase ( ALP ) ≤ 2.5 x institutional upper limit normal ( ULN ) 2 . Bilirubin ≤ 1.5 time institutional ULN Renal function : eGFR &gt; 50ml/min • Metabolic Function : 1 . Magnesium ≥ low limit normal 2 . Calcium ≥ low limit normal . No imminent bowel obstruction . No active bleeding . No uncontrolled infection . Patients reproductive potential must use effective contraception . Female patient must negative pregnancy test . Signed informed consent . Participation another therapeutic clinical study within 30 day enrollment clinical study . No adequate radiation therapy possible : base opinion radiation oncologist radiation therapy perform radiation field large ( PTV volume large OAR high ) History allergic reaction gemcitabine antibody treatment . Presence serious concomitant systemic disorder incompatible clinical study ( e.g . uncontrolled intercurrent illness include ongoing active infection , uncontrolled hypertension ) . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) within 1 year enrolment/randomization History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance . Pregnant breastfeed woman . Absence adequate contraception male female fertile patient duration study ; also six month last treatment . Known positive status HIV and/or hepatitis B C. Any reason , investigator 's opinion , patient participate study . Drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Panitumumab</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Inoperable</keyword>
</DOC>